Takeda Starts Vedolizumab Phase III Trials For Crohn’s Disease, Ulcerative Colitis
This article was originally published in PharmAsia News
Executive Summary
Takeda initiated Japenese Phase III trials with the monoclonal antibody vedolizumab used in the treatment of moderate to severe ulcerative colitis and Crohn’s disease.